Market Overview:
The global rapid acting insulin market size reached US$ 7 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 9.3 Billion by 2027, exhibiting a growth rate (CAGR) of 5.2% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Rapid acting insulin is a medication used to control glucose levels in patients with diabetes. It is either inhaled or administered into the bloodstream with a syringe, a pre-filled pen, or an insulin pump. It is taken prior to meals and snacks to bring overly high blood glucose to a normal level and surge the level of bolus insulin. At present, new insulin formulations like novel ultra-paid-acting insulins that enhance absorption are considered a suitable option for people who cannot achieve postprandial glycemic targets with other bolus insulins.
www.imarcgroup.com
Note: Values and trends in the above chart consists of dummy data and are only shown here for representation purpose. Kindly contact us for the actual market size and trends.
Rapid Acting Insulin Market Trends:
Diabetes mellitus (DM) and poorly controlled blood glucose can increase the risk of mortality and severity among patients with coronavirus disease (COVID-19). This represents one of the key factors fueling the need for rapid acting insulins to monitor blood glucose levels. Apart from this, the growing prevalence of type 1 diabetes on account of exposure to viruses and other environmental factors and low levels of vitamin D acts as another factor propelling the demand for rapid acting insulins across the globe. This can also be attributed to the increasing instances of neonatal jaundice in newborns, in confluence with improving diagnostic modalities. In addition to this, as the risk of developing diabetes increases with age, the rising global geriatric population is facilitating the market growth. Furthermore, leading market players are introducing ready-to-use rapid acting insulin kits that are fast, accessible in vials and a pen presentation, and help enhance glycemic control in both adults and children. These players are also focusing on mergers and acquisitions (M&A), which is anticipated to contribute to the development of new-generation product variants.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global rapid acting insulin market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on product, indication and distribution channel.
Breakup by Product:
www.imarcgroup.com
Note: Values and trends in the above chart consists of dummy data and are only shown here for representation purpose. Kindly contact us for the actual market size and trends.
- Lispro Insulin
- Aspart Insulin
- Glulisine Insulin
Breakup by Indication:
- Type 1 Diabetes
- Type 2 Diabetes
Breakup by Distribution Channel:
- Hospital Pharmacies
- Drug Stores and Retail Pharmacies
- Online Stores
Breakup by Region:
To get more information on the regional analysis of this market, Request Sample
- North America
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Adocia, Biocon Limited, Eli Lilly and Company, Gan & Lee Pharmaceuticals Co. Ltd., Geropharm, MannKind Corporation, Merck & Co. Inc., Novo Nordisk A/S, Sanofi S.A., and Wockhardt Ltd.
Report Coverage:
| Report Features |
Details |
|---|
| Base Year of the Analysis |
2021 |
| Historical Period |
2016-2021 |
| Forecast Period |
2022-2027 |
| Units |
US$ Billion |
| Segment Coverage |
Product, Indication, Distribution Channel, Region |
| Region Covered |
Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
| Countries Covered |
United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
| Companies Covered |
Adocia, Biocon Limited, Eli Lilly and Company, Gan & Lee Pharmaceuticals Co. Ltd., Geropharm, MannKind Corporation, Merck & Co. Inc., Novo Nordisk A/S, Sanofi S.A., and Wockhardt Ltd. |
| Customization Scope |
10% Free Customization |
| Report Price and Purchase Option |
Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499 |
| Post-Sale Analyst Support |
10-12 Weeks |
| Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
Key Questions Answered in This Report:
- How has the global rapid acting insulin market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global rapid acting insulin market?
- What are the key regional markets?
- What is the breakup of the market based on the product?
- What is the breakup of the market based on the indication?
- What is the breakup of the market based on the distribution channel?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global rapid acting insulin market and who are the key players?
- What is the degree of competition in the industry?
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Rapid Acting Insulin Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Product
6.1 Lispro Insulin
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Aspart Insulin
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Glulisine Insulin
6.3.1 Market Trends
6.3.2 Market Forecast
7 Market Breakup by Indication
7.1 Type 1 Diabetes
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Type 2 Diabetes
7.2.1 Market Trends
7.2.2 Market Forecast
8 Market Breakup by Distribution Channel
8.1 Hospital Pharmacies
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Drug Stores and Retail Pharmacies
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Online Stores
8.3.1 Market Trends
8.3.2 Market Forecast
9 Market Breakup by Region
9.1 North America
9.1.1 United States
9.1.1.1 Market Trends
9.1.1.2 Market Forecast
9.1.2 Canada
9.1.2.1 Market Trends
9.1.2.2 Market Forecast
9.2 Asia-Pacific
9.2.1 China
9.2.1.1 Market Trends
9.2.1.2 Market Forecast
9.2.2 Japan
9.2.2.1 Market Trends
9.2.2.2 Market Forecast
9.2.3 India
9.2.3.1 Market Trends
9.2.3.2 Market Forecast
9.2.4 South Korea
9.2.4.1 Market Trends
9.2.4.2 Market Forecast
9.2.5 Australia
9.2.5.1 Market Trends
9.2.5.2 Market Forecast
9.2.6 Indonesia
9.2.6.1 Market Trends
9.2.6.2 Market Forecast
9.2.7 Others
9.2.7.1 Market Trends
9.2.7.2 Market Forecast
9.3 Europe
9.3.1 Germany
9.3.1.1 Market Trends
9.3.1.2 Market Forecast
9.3.2 France
9.3.2.1 Market Trends
9.3.2.2 Market Forecast
9.3.3 United Kingdom
9.3.3.1 Market Trends
9.3.3.2 Market Forecast
9.3.4 Italy
9.3.4.1 Market Trends
9.3.4.2 Market Forecast
9.3.5 Spain
9.3.5.1 Market Trends
9.3.5.2 Market Forecast
9.3.6 Russia
9.3.6.1 Market Trends
9.3.6.2 Market Forecast
9.3.7 Others
9.3.7.1 Market Trends
9.3.7.2 Market Forecast
9.4 Latin America
9.4.1 Brazil
9.4.1.1 Market Trends
9.4.1.2 Market Forecast
9.4.2 Mexico
9.4.2.1 Market Trends
9.4.2.2 Market Forecast
9.4.3 Others
9.4.3.1 Market Trends
9.4.3.2 Market Forecast
9.5 Middle East and Africa
9.5.1 Market Trends
9.5.2 Market Breakup by Country
9.5.3 Market Forecast
10 SWOT Analysis
10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 Adocia
14.3.1.1 Company Overview
14.3.1.2 Product Portfolio
14.3.1.3 Financials
14.3.2 Biocon Limited
14.3.2.1 Company Overview
14.3.2.2 Product Portfolio
14.3.2.3 Financials
14.3.2.4 SWOT Analysis
14.3.3 Eli Lilly and Company
14.3.3.1 Company Overview
14.3.3.2 Product Portfolio
14.3.3.3 Financials
14.3.3.4 SWOT Analysis
14.3.4 Gan & Lee Pharmaceuticals Co. Ltd.
14.3.4.1 Company Overview
14.3.4.2 Product Portfolio
14.3.4.3 Financials
14.3.5 Geropharm
14.3.5.1 Company Overview
14.3.5.2 Product Portfolio
14.3.6 MannKind Corporation
14.3.6.1 Company Overview
14.3.6.2 Product Portfolio
14.3.6.3 Financials
14.3.6.4 SWOT Analysis
14.3.7 Merck & Co. Inc.
14.3.7.1 Company Overview
14.3.7.2 Product Portfolio
14.3.7.3 Financials
14.3.7.4 SWOT Analysis
14.3.8 Novo Nordisk A/S
14.3.8.1 Company Overview
14.3.8.2 Product Portfolio
14.3.8.3 Financials
14.3.8.4 SWOT Analysis
14.3.9 Sanofi S.A.
14.3.9.1 Company Overview
14.3.9.2 Product Portfolio
14.3.9.3 Financials
14.3.9.4 SWOT Analysis
14.3.10 Wockhardt Ltd.
14.3.10.1 Company Overview
14.3.10.2 Product Portfolio
14.3.10.3 Financials
List of Figures
Figure 1: Global: Rapid Acting Insulin Market: Major Drivers and Challenges
Figure 2: Global: Rapid Acting Insulin Market: Sales Value (in Billion US$), 2016-2021
Figure 3: Global: Rapid Acting Insulin Market Forecast: Sales Value (in Billion US$), 2022-2027
Figure 4: Global: Rapid Acting Insulin Market: Breakup by Product (in %), 2021
Figure 5: Global: Rapid Acting Insulin Market: Breakup by Indication (in %), 2021
Figure 6: Global: Rapid Acting Insulin Market: Breakup by Distribution Channel (in %), 2021
Figure 7: Global: Rapid Acting Insulin Market: Breakup by Region (in %), 2021
Figure 8: Global: Rapid Acting Insulin (Lispro Insulin) Market: Sales Value (in Million US$), 2016 & 2021
Figure 9: Global: Rapid Acting Insulin (Lispro Insulin) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 10: Global: Rapid Acting Insulin (Aspart Insulin) Market: Sales Value (in Million US$), 2016 & 2021
Figure 11: Global: Rapid Acting Insulin (Aspart Insulin) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 12: Global: Rapid Acting Insulin (Glulisine Insulin) Market: Sales Value (in Million US$), 2016 & 2021
Figure 13: Global: Rapid Acting Insulin (Glulisine Insulin) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 14: Global: Rapid Acting Insulin (Type 1 Diabetes) Market: Sales Value (in Million US$), 2016 & 2021
Figure 15: Global: Rapid Acting Insulin (Type 1 Diabetes) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 16: Global: Rapid Acting Insulin (Type 2 Diabetes) Market: Sales Value (in Million US$), 2016 & 2021
Figure 17: Global: Rapid Acting Insulin (Type 2 Diabetes) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 18: Global: Rapid Acting Insulin (Hospital Pharmacies) Market: Sales Value (in Million US$), 2016 & 2021
Figure 19: Global: Rapid Acting Insulin (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 20: Global: Rapid Acting Insulin (Drug Stores and Retail Pharmacies) Market: Sales Value (in Million US$), 2016 & 2021
Figure 21: Global: Rapid Acting Insulin (Drug Stores and Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 22: Global: Rapid Acting Insulin (Online Stores) Market: Sales Value (in Million US$), 2016 & 2021
Figure 23: Global: Rapid Acting Insulin (Online Stores) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 24: North America: Rapid Acting Insulin Market: Sales Value (in Million US$), 2016 & 2021
Figure 25: North America: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 26: United States: Rapid Acting Insulin Market: Sales Value (in Million US$), 2016 & 2021
Figure 27: United States: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 28: Canada: Rapid Acting Insulin Market: Sales Value (in Million US$), 2016 & 2021
Figure 29: Canada: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 30: Asia-Pacific: Rapid Acting Insulin Market: Sales Value (in Million US$), 2016 & 2021
Figure 31: Asia-Pacific: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 32: China: Rapid Acting Insulin Market: Sales Value (in Million US$), 2016 & 2021
Figure 33: China: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 34: Japan: Rapid Acting Insulin Market: Sales Value (in Million US$), 2016 & 2021
Figure 35: Japan: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 36: India: Rapid Acting Insulin Market: Sales Value (in Million US$), 2016 & 2021
Figure 37: India: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 38: South Korea: Rapid Acting Insulin Market: Sales Value (in Million US$), 2016 & 2021
Figure 39: South Korea: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 40: Australia: Rapid Acting Insulin Market: Sales Value (in Million US$), 2016 & 2021
Figure 41: Australia: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 42: Indonesia: Rapid Acting Insulin Market: Sales Value (in Million US$), 2016 & 2021
Figure 43: Indonesia: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 44: Others: Rapid Acting Insulin Market: Sales Value (in Million US$), 2016 & 2021
Figure 45: Others: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 46: Europe: Rapid Acting Insulin Market: Sales Value (in Million US$), 2016 & 2021
Figure 47: Europe: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 48: Germany: Rapid Acting Insulin Market: Sales Value (in Million US$), 2016 & 2021
Figure 49: Germany: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 50: France: Rapid Acting Insulin Market: Sales Value (in Million US$), 2016 & 2021
Figure 51: France: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 52: United Kingdom: Rapid Acting Insulin Market: Sales Value (in Million US$), 2016 & 2021
Figure 53: United Kingdom: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 54: Italy: Rapid Acting Insulin Market: Sales Value (in Million US$), 2016 & 2021
Figure 55: Italy: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 56: Spain: Rapid Acting Insulin Market: Sales Value (in Million US$), 2016 & 2021
Figure 57: Spain: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 58: Russia: Rapid Acting Insulin Market: Sales Value (in Million US$), 2016 & 2021
Figure 59: Russia: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 60: Others: Rapid Acting Insulin Market: Sales Value (in Million US$), 2016 & 2021
Figure 61: Others: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 62: Latin America: Rapid Acting Insulin Market: Sales Value (in Million US$), 2016 & 2021
Figure 63: Latin America: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 64: Brazil: Rapid Acting Insulin Market: Sales Value (in Million US$), 2016 & 2021
Figure 65: Brazil: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 66: Mexico: Rapid Acting Insulin Market: Sales Value (in Million US$), 2016 & 2021
Figure 67: Mexico: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 68: Others: Rapid Acting Insulin Market: Sales Value (in Million US$), 2016 & 2021
Figure 69: Others: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 70: Middle East and Africa: Rapid Acting Insulin Market: Sales Value (in Million US$), 2016 & 2021
Figure 71: Middle East and Africa: Rapid Acting Insulin Market: Breakup by Country (in %), 2021
Figure 72: Middle East and Africa: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 73: Global: Rapid Acting Insulin Industry: SWOT Analysis
Figure 74: Global: Rapid Acting Insulin Industry: Value Chain Analysis
Figure 75: Global: Rapid Acting Insulin Industry: Porter's Five Forces Analysis
List of Tables
Table 1: Global: Rapid Acting Insulin Market: Key Industry Highlights, 2021 and 2027
Table 2: Global: Rapid Acting Insulin Market Forecast: Breakup by Product (in Million US$), 2022-2027
Table 3: Global: Rapid Acting Insulin Market Forecast: Breakup by Indication (in Million US$), 2022-2027
Table 4: Global: Rapid Acting Insulin Market Forecast: Breakup by Distribution Channel (in Million US$), 2022-2027
Table 5: Global: Rapid Acting Insulin Market Forecast: Breakup by Region (in Million US$), 2022-2027
Table 6: Global: Rapid Acting Insulin Market: Competitive Structure
Table 7: Global: Rapid Acting Insulin Market: Key Players